ARWR (Arrowhead Pharma) Earnings per share for the last twelve months

Public company logo of Arrowhead Pharmaceuticals Inc (ARWR)

The absence of commercial products and reliance on partner payments drive volatility, causing the annual EPS TTM trend to exhibit instability, with the current mark at -11527.80. Meanwhile, Arrowhead Pharmaceuticals (ARWR) maintains margins through its leadership in RNA interference and alliances with industry behemoths. Simultaneously, the company is implementing energy-saving systems and strict emission controls in its laboratories to comply with ESG standards.

arrowheadpharma.com (ARWR): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

ARWR (Arrowhead Pharmaceuticals): analytical breakdowns and indicator data

Initial company analysis:Arrowhead Pharma ARWR
Mass-produced product of Arrowhead Corp

For Arrowhead Pharmaceuticals (ARWR), whose potential depends on the commercialization of RNAi therapy, the YoY TTM earnings per share dynamics reflect the efficiency of the transition from development to sales. This indicator measures the percentage change in net income per share over the last twelve months relative to the previous year, allowing investors to detect trend reversals and assess the risk of asset overvaluation should results deviate from expectations.